NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $3.66 -0.12 (-3.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRWD alerts:Sign Up Key Stats Today's Range$3.58▼$3.8150-Day Range$3.34▼$4.6152-Week Range$3.06▼$15.70Volume1.86 million shsAverage Volume2.32 million shsMarket Capitalization$585.71 millionP/E RatioN/ADividend YieldN/APrice Target$10.40Consensus RatingModerate Buy Company OverviewIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More… Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 138th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has received no research coverage in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth162.50% Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 162.50% in the coming year, from $0.08 to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -122.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -122.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.92% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 23.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.94 Percentage of Shares Shorted5.92% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 23.68%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.58 News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ironwood Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $66,753.00 in company stock.Percentage Held by Insiders12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Stock News HeadlinesIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 3.7% - Should You Sell?January 19 at 4:07 AM | americanbankingnews.comOzempic, Xtandi among next 15 drugs selected for U.S. price talksJanuary 18 at 1:43 AM | markets.businessinsider.comThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one virtually unknown coin could thrive in the first year of Trump's crypto bull market …starting during his first week in office.January 20, 2025 | Weiss Ratings (Ad)Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medicationsJanuary 17 at 8:07 AM | cnbc.comWhat is Zacks Research's Forecast for IRWD FY2026 Earnings?January 13, 2025 | americanbankingnews.comIronwood Pharma (IRWD) Receives a Buy from Craig-HallumDecember 20, 2024 | markets.businessinsider.comIronwood Pharmaceuticals shares surge on competitor's woesDecember 20, 2024 | in.investing.comIronwood jumps after FDA rejects Zealand short bowel syndrome drug applicationDecember 20, 2024 | tipranks.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $4.43 at the start of the year. Since then, IRWD shares have decreased by 17.4% and is now trading at $3.66. View the best growth stocks for 2025 here. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.07. The company's revenue was down 19.4% compared to the same quarter last year. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' top institutional investors include Wedge Capital Management L L P NC (0.18%), Hennion & Walsh Asset Management Inc. (0.12%), Harbor Capital Advisors Inc. (0.06%) and Inspire Investing LLC (0.06%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Andrew Davis, Minardo John, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings11/07/2024Today1/20/2025Next Earnings (Estimated)2/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$10.40 High Stock Price Target$21.00 Low Stock Price Target$4.00 Potential Upside/Downside+184.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E Ratio45.75 P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins-0.65% Pretax Margin18.91% Return on Equity-0.96% Return on Assets0.74% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$442.73 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-1.66Miscellaneous Outstanding Shares160,030,000Free Float139,384,000Market Cap$585.71 million OptionableOptionable Beta0.34 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:IRWD) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.